Overview
This study evaluates hematopoiesis to determine how MBL/CLL affected bone marrow responds to fight off infections in the body.
Description
PRIMARY OBJECTIVES:
I. Determine the cellular and mechanistic basis of bone marrow (BM) hematopoietic dysfunction in untreated MBL and CLL patients.
II. Determine if MBL and CLL B cell derived cellular products directly alter the differentiation and functional capacities of Hematopoietic Stem and Progenitor Cells (HSPCs).
III. Utilize the Emu-Tcl1 transgenic mouse model to determine how MBL and CLL patient-derived cellular products alter BM hematopoiesis.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and bone marrow aspiration and biopsy and have their medical records reviewed on study.
Eligibility
Inclusion Criteria:
- Subjects in the CLL cohort who are eligible for these studies will have a clinically
established diagnosis of CLL as assessed by flow cytometry and will include subjects
who
- Remain untreated
- Are currently being treated
- Who have already been treated
- Subjects in the MBL cohort will have a clinically established diagnosis of MBL
- Healthy age-matched control subjects
- Healthy younger control subjects aged > 40 years
Exclusion Criteria:
- Anyone under 40
- Healthy control subjects must not have a diagnosis of CLL or MBL